Novo Nordisk has announced the permanent discontinuation of all formulations of Levemir. Supply disruptions of Levemir FlexPen are expected to begin in mid-January 2024, followed by the complete discontinuation of the FlexPen on April 1, 2024. The Levemir vial will be discontinued on December 31, 2024.
Novo Nordisk will continue to provide Levemir to pharmacies and wholesalers while supplies last. In order to maintain continuity of care, patients using Levemir are encouraged to discuss alternative treatment options with their healthcare provider before products are no longer available.
For patients on Medicaid, Levemir will remain preferred on the Preferred Drug List (PDL) so that claims will continue to pay until any remaining stock is depleted.